TICKERNERD
Menu
NRSNNRSNHealthcare · Biotechnology

NRSN Stock Forecast: Neurosense Therapeutics Ltd. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$0.51
+27.11% on the day

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. hold a median 12-month price target of $7.5 — +1367.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 5 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$19.3M
Ticker Nerd rank
2 / 100
Median analyst target
$7.50
Analysts covering
3
Revenue$0.0
Operating income−$1.8M
Net income−$1.8M
Quarterly, 6 quarters to 31 Dec 2024 · latest quarter's figure shown
Total return, dividends reinvested
1W
+21.7%
1M
−1.7%
YTD
−33.6%
1Y
−53.5%
From 52W high
−62.4%
From 52W low
+46.0%
$0.35
$1.36
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NRSN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurosense Therapeutics Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
2 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Revisions
31
Volatility
29
Growth
8
Accruals
8
Momentum
7
Value
5
Quality
4
Issuance
0

Size (89): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NRSN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NRSN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26NRSNHigh $9.00Median $7.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $3.00Median $7.50High $9.00

The green dot is the last close — the median target sits +1367.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Sept 2026HC Wainwright & Co.InitiatesBuy$8.00
8 Apr 2026D. Boral CapitalMaintainsBuy$14
8 Apr 2026D. Boral CapitalMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
17 Mar 2026D. Boral CapitalMaintainsBuy—
10 Mar 2026Roth CapitalInitiatesBuy—
9 Mar 2026D. Boral CapitalMaintainsBuy—
22 Dec 2025D. Boral CapitalMaintainsBuy—
24 Nov 2025D. Boral CapitalMaintainsBuy—
15 Aug 2025D. Boral CapitalMaintainsBuy—
10 July 2025D. Boral CapitalMaintainsBuy—
12 May 2025D. Boral CapitalInitiatesBuy—
16 Dec 2024Maxim GroupDowngradeHold—
17 July 2023Alliance Global PartnersInitiatesBuy$7.50
7 Jan 2022Maxim GroupInitiatesBuy$7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NRSN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

NRSN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Neurosense Therapeutics Ltd. returned −53.5% against +20.0% for the S&P 500, dividends included.

NRSN vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26NRSNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NRSN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Neurosense Therapeutics Ltd. (NRSN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.2×

Cheaper than 83% of US stocks

Price / sales
—
Price / book
—
EV / EBITDA
−1.6×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−2175.0%

Higher than 1% of US stocks

Return on assets
−247.3%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurosense Therapeutics Ltd. (NRSN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurosense Therapeutics Ltd. has a market value of $19.3M and an enterprise value of $18.1M.

  • Revenue in the twelve months to 31 Dec 2024: $0.0.

  • Net income over the same four quarters: −$10.2M.

  • Shares outstanding: 32.6M.

  • Trailing P/E: −1.2×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Neurosense Therapeutics Ltd. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Dec 2024 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

NRSN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NRSNNeurosense Therapeutics Ltd.$19.3M
2
KTTAPasithea Therapeutics Corp.$19.4M
13
LPCNLipocine, Inc.$19.7M
38
MRKRMarker Therapeutics, Inc.$19.7M
52
CYCNCyclerion Therapeutics, Inc.$19.9M
28
ADILAdial Pharmaceuticals, Inc.$18.7M
20
ENLVEnlivex Ltd.$18.5M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurosense Therapeutics Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NRSN news & analysis

NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS

PRNewsWire · 31 Aug 2026positive

NeuroSense Therapeutics announced an accelerated, capital-efficient strategy to advance its ALS candidate PrimeC toward potential approval. The program includes AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, a streamlined pivotal pathway, and a parallel regulatory pathway in Canada, aimed at strengthening differentiation, shortening time to commercialization, and reducing development costs.

Why it matters — NRSN watchers would care because this strategy could shorten the timeline to potential commercialization of PrimeC while significantly lowering overall development costs.

NeuroSense Issues CEO Letter to Shareholders

PRNewsWire · 13 Aug 2026neutral

NeuroSense Therapeutics Ltd. issued a letter to shareholders on August 13, 2026, as announced in a press release from its Cambridge, Mass. headquarters.

Why it matters — A CEO letter to shareholders often provides updates on company strategy, milestones, or outlook, making it a key communication for NRSN watchers.

NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

PRNewsWire · 6 Aug 2026positive

NeuroSense Therapeutics announced completion of the PrimeC pre-New Drug Submission (pre-NDS) process, with final meeting minutes confirming alignment with Health Canada on the planned content and structure of the ALS submission. The company is advancing toward filing with Health Canada in December 2026.

Why it matters — NRSN watchers would care because this regulatory milestone brings PrimeC closer to a formal Health Canada submission for ALS treatment, marking clear progress in the company's approval pathway.

FAQ

Frequently asked questions about NRSN stock

What is the NRSN stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Neurosense Therapeutics Ltd. have a median 12-month price target of $7.5, with estimates ranging from $3 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NRSN stock a buy right now?

Of the 3 analysts covering Neurosense Therapeutics Ltd., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurosense Therapeutics Ltd. 2 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NRSN?

As at 5 Sept 2026, Neurosense Therapeutics Ltd. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will NRSN stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1367.7% from the last close, and Ticker Nerd's factor model ranks Neurosense Therapeutics Ltd. 2 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NRSN stock forecast for 2030?

No analyst covering Neurosense Therapeutics Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NRSN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $9 over the next 12 months.

How has NRSN stock performed over the past year?

Neurosense Therapeutics Ltd. returned -53.5% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurosense Therapeutics Ltd. do?

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases.

What is the latest news on NRSN?

The most recent item we track (PRNewsWire, 31 Aug 2026): "NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS". NeuroSense Therapeutics announced an accelerated, capital-efficient strategy to advance its ALS candidate PrimeC toward potential approval. The program includes AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, a streamlined pivotal pathway, and a parallel regulatory pathway in Canada, aimed at strengthening differentiation, shortening time to commercialization, and reducing development costs.

Company

About Neurosense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead program, PrimeC, is an oral combination therapy designed for amyotrophic lateral sclerosis (ALS), while its broader pipeline includes research programs for Alzheimer’s disease and Parkinson’s disease. The company develops targeted therapeutic approaches intended to address complex neurological conditions with significant unmet medical need. NeuroSense Therapeutics Ltd. operates in the global biopharmaceutical market, where it contributes to the advancement of novel drug candidates through clinical and preclinical development. Based in Herzliya, Israel, the company is positioned within the specialized field of neuroscience-focused drug discovery and development.

CEO Mr. Alon Ben-Noon · 17 employees · Israel · https://www.neurosense-tx.com